ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1339

Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors
Abstract Number: 1340

Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?
Abstract Number: 1341

Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Abstract Number: 1342

The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Abstract Number: 1343

Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
Abstract Number: 1344

Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 1345

Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
Abstract Number: 1346

Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
Abstract Number: 1347

The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1348

Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Abstract Number: 1349

Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis in a Real-World Setting: Final 2-year Outcomes from the UPHOLD Study
Abstract Number: 1350

Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Abstract Number: 1351

Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Abstract Number: 1352

Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Abstract Number: 1353

Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].